GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » Price-to-Free-Cash-Flow

Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Price-to-Free-Cash-Flow

: 27.73 (As of Today)
View and export this data going back to 1991. Start your Free Trial

As of today (2024-04-18), Regeneron Pharmaceuticals's share price is $893.99. Regeneron Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $32.24. Hence, Regeneron Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is 27.73.

The historical rank and industry rank for Regeneron Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

REGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.17   Med: 35.41   Max: 1102.82
Current: 27.72

During the past 13 years, Regeneron Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 1102.82. The lowest was 8.17. And the median was 35.41.

REGN's Price-to-Free-Cash-Flow is ranked better than
52.86% of 210 companies
in the Biotechnology industry
Industry Median: 30.53 vs REGN: 27.72

Regeneron Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $6.83. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $32.24.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Regeneron Pharmaceuticals was 7.70% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 22.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 20.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 29.10% per year.

During the past 13 years, Regeneron Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 54.50% per year. The lowest was -75.40% per year. And the median was 21.40% per year.


Regeneron Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Regeneron Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.51 27.75 10.85 24.10 27.23

Regeneron Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.10 37.16 27.31 21.50 27.23

Competitive Comparison

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Regeneron Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Regeneron Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=893.99/32.239
=27.73

Regeneron Pharmaceuticals's Share Price of today is $893.99.
Regeneron Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.24.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Regeneron Pharmaceuticals  (NAS:REGN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Regeneron Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Executives
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Arthur F Ryan director CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
George Yancopoulos director, officer: President and CSO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Huda Y Zoghbi director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Marion Mccourt officer: SVP Commercial C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael S Brown director
Christopher R. Fenimore officer: VP, Controller REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Andrew J Murphy officer: EVP Research REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Kathryn Guarini director 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Van Plew Daniel P officer: EVP & General Mgr Industrial O REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Robert E Landry officer: SVP Fin, Dep CFO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Neil Stahl officer: SVP, Preclinical Development 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein director DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390